BILLERICA, Mass. — Bruker Corporation has named Thierry L. Bernard to its Board of Directors, adding an experienced life sciences and diagnostics executive to its leadership team.
The appointment is effective immediately, the company said, as it continues to expand its presence in life science research, biopharma and diagnostic technologies.
Frank H. Laukien, Chairman, President and Chief Executive Officer of Bruker, said Bernard brings a strong track record in strategic leadership and operational execution.
“Bruker is delighted that Thierry is joining our Board. I have admired his successful track record, astute strategic initiatives, and outstanding execution for many years, and I am convinced that Thierry will be an excellent addition to our Board of Directors as we further develop our leadership position in life-science research, biopharma, and diagnostic solutions in the post-genomic era, and aim for profitable growth and rapid margin expansion to enhance stakeholder value,” Laukien said.
Bernard currently serves as Chief Executive Officer of QIAGEN N.V., a role he assumed in 2019 after joining the company in 2015 to lead its molecular diagnostics business. He has announced plans to step down as CEO once a successor is appointed.
Before joining QIAGEN, Bernard spent 15 years at bioMérieux SA, where he held senior roles including Corporate Vice President for Global Commercial Operations, Investor Relations and the Greater China region. He has also held leadership positions at several international companies.
In addition to his corporate roles, Bernard was named Chair of the Board of Directors of AdvaMedDx in 2023 and joined the board of Neogen Corporation in 2024.
“I am very pleased to join Bruker’s Board of Directors. I have long admired its significant contributions to scientific research and improving patient outcomes,” Bernard said. “Bruker’s high-performance technologies and global footprint position it well to enable a deeper understanding of biology to support more precise diagnostics, more effective therapies and ultimately better healthcare. I look forward to supporting its continued development and commitment to long-term value creation.”
Bernard holds degrees and certifications from Sciences Po Paris, the London School of Economics, the College of Europe, Harvard Business School and Centro de Comercio Exterior de Barcelona.
